Cellumen, Inc. Launches Rat Cardiomyocyte Early Safety Assessment Panel, Signs Contract with International Biotech Company

PITTSBURGH--(BUSINESS WIRE)--Cellumen, Inc., a discovery and early safety assessment company, today announced that it has added a Rat Cardiomyocyte Panel to its CellCiphr® Early Safety Assessment services. Derived from embryonic rodent hearts, Cellumen’s Rat Cardiomyocyte Panel will identify toxic compounds and their corresponding mechanisms of toxicity with unprecedented sensitivity and specificity earlier in the drug development process.